All Respiratory articles
-
InformationKey COVID-19 guidance for community pharmacy
The Guidelines for Pharmacy team has produced the following directory of COVID-19 information and guidance for community pharmacy. Included on this page is a collection of key guidance and advice from PSNC, FIP, and NHS, as well as a list of information for specific groups from a range of professional bodies.
-
Information
Key COVID-19 guidance for primary care
The Guidelines team has produced the following directory of COVID-19 information and guidance for primary care. Included on this page is a collection of key guidance and advice from PHE and the NHS, as well as a list of information for specific groups from a range of professional bodies.
-
Hosted content
COPD: LAMA/LABA therapy—Real life case studies
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200015 V2.0 -
Hosted content
COPD: LAMA/LABA as initial maintenance therapy for appropriate symptomatic patients
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200014 V2.0 -
News
GOLD COPD report 2021 published
GOLD has published its annual report on chronic obstructive lung disease, used worldwide by healthcare experts
-
Hosted content
Why you might want to review patients with COPD receiving a LAMA
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200013 -
Hosted content
COPD: Have you done enough to implement guidelines?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200012 -
Hosted content
Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200011 -
Prescribing summary card
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Click here for prescribing information and adverse event reporting.
DUOR-GB-00021
Date of preparation: August 2020 -
NICE guideline
COVID-19 rapid guideline: cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.
-
Independent professional body guideline
AWMSG asthma guideline
Core principles of asthma management, inhaler selection and use, and referral guidance, from the All Wales Medicines Strategy Group
-
Hosted content
Fostair (beclometasone/formoterol): key messages
This promotional resource has been commissioned and developed by Chiesi Limited. Information intended for UK healthcare professionals only.
Click here for Prescribing Information and Adverse Event Reporting.
UK-NEX-2000037 November 2020 -
Hosted content
Fostair (beclometasone/formoterol): key messages
This promotional resource has been commissioned and developed by Chiesi Limited. Information intended for UK healthcare professionals only.
Click here for Prescribing Information and Adverse Event Reporting.
UK-NEX-2000037 November 2020 -
Working party guideline/algorithm
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
-
Independent professional body guideline
BTS/SIGN asthma in pregnancy guideline
This summary focuses on recommendations for the management of asthma in pregnant women, including during labour, and recommendations for breastfeeding mothers
-
Information
GINA ASTHMA STRATEGY 2020
Asthma affects an estimated 300 million individuals worldwide, and still imposes an unacceptable burden on healthcare systems, society through loss of productivity in the workplace, and, especially for paediatric asthma, disruption to the family. Asthma affects all age groups and contributes to many deaths worldwide. The Global Initiative for ...
-
Working party guideline/algorithm
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
-
Independent professional body guideline
GINA strategy 2020: assessing patients with asthma
This Guidelines summary outlines recommendations for assessing patients with asthma. Please refer to the full report for the complete set of recommendations.
-
Independent professional body guideline
GINA strategy 2020: management of asthma
This Guidelines summary outlines recommendations for the management of asthma in adults, adolescents, and children aged six to 11.
-
Independent professional body guideline
GINA strategy 2020: asthma–COPD overlap
This Guidelines summary outlines recommendations for the diagnosis and initial treatment of adults with features of asthma, chronic obstructive pulmonary disease (COPD), or both.
